CHOLECYSTOKININ ANTAGONISTS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13848
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1990
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Peptide Technologies Corp
125 Michigan Ave Ne #368 Main, Washington, DC, 20017
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Martha Knight
 (202) 234-3384
Business Contact
Phone: () -
Research Institution
N/A
Abstract
POSSIBLE THERAPEUTICS FOR NEUROENDOCRINE AND GASTROINTESTINAL TUMORS AND NEUROPSYCHIATRIC DISEASES MAY BE DEVELOPED FROM PEPTIDE ANTAGONISTS OF THE CENTRAL NERVOUSSYSTEM CHOLECYSTOKININ RECEPTOR. STRUCTURALLY MODIFIED CHOLECYSTOKININ OCTAPEPTIDE FRAGMENTS WILL BE TESTED FOR INTERACTION WITH CHOLECYSTOKININ RECEPTORS IN A NEUROENDOCRINE CELL LINE, HUMAN SMALL-CELL LUNG CARCINOMA. THESE COMPOUNDS, MORE CLOSELY RESEMBLING NATURALLY OCCURRINGNEUROPEPTIDES, SHOULD CROSS-REACT LESS WITH OTHER CENTRAL NERVOUS SYSTEM RECEPTORS, RESULTING IN FEWER UNDESIRABLE SIDE EFFECTS. POTENT COMPOUNDS IDENTIFIED IN THE CELL ASSAYWILL BE FURTHER EVALUATED IN PHARMACOLOGICAL PRECLINICAL STUDIES IN THE PHASE II RESEARCH.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government